Form 4: Incyte EVP & Chief Medical Officer Reports Share Sale and New Equity Awards

Incyte Corporation's EVP & Chief Medical Officer, Steven H. Stein, reported the sale of common stock and the acquisition of new restricted stock units, performance shares, and employee stock options.

Summary

• Steven H. Stein, EVP & Chief Medical Officer of Incyte Corp, sold 14,952 shares of common stock at $68.47 on July 14, 2025.
• An additional 1,555 shares and 1,596 shares were withheld on July 14, 2025, and July 15, 2025, respectively, to cover tax withholding obligations related to previously vested equity.
• On July 15, 2025, Stein was awarded 12,277 restricted stock units (RSUs) which will vest 25% annually over four years.
• He also received 30,692 performance shares on July 15, 2025, which can yield up to 200% of one share based on Incyte's relative total shareholder return (TSR) over a three-year period starting January 1, 2025, vesting on July 15, 2028.
• Furthermore, 27,629 employee stock options with an exercise price of $68.25 were granted on July 15, 2025, vesting over approximately four years with a 10-year expiration.
• Following these transactions, Stein directly beneficially owns 94,315 shares of common stock, along with 100,327 unvested shares from previously reported RSUs and earned performance shares, 30,692 performance shares, and 27,629 employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there was a sale of shares, which can sometimes be viewed negatively, it was offset by significant new equity awards (RSUs, performance shares, and stock options) that align the executive's long-term incentives with the company's performance. The transaction was also conducted under a 10b5-1 plan, suggesting a pre-planned, non-opportunistic sale.

Positives

• Grant of 12,277 Restricted Stock Units (RSUs) aligns management incentives with long-term shareholder value.
• Award of 30,692 Performance Shares, tied to relative Total Shareholder Return (TSR) over three years, further incentivizes strong company performance.
• Grant of 27,629 Employee Stock Options provides additional long-term incentive for the executive.
• Transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled and not opportunistic trading.

Negatives

• Sale of 14,952 shares of common stock by a key executive, Steven H. Stein, at $68.47.

Future Outlook

The vesting schedules for RSUs (25% annually over four years), performance shares (vesting on July 15, 2028, based on TSR performance), and employee stock options (vesting over approximately four years) indicate a long-term incentive structure for the executive, aligning future performance with compensation.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industries, where a significant portion of executive pay is often equity-based, including restricted stock units, performance shares, and stock options, designed to align executive interests with long-term shareholder value. The sale of shares is a common occurrence for executives to manage personal liquidity or tax obligations.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived negatively, but the simultaneous grant of new, performance-based equity awards (RSUs, performance shares, stock options) aligns the executive's long-term interests with shareholder value creation. The 10b5-1 plan indicates a pre-scheduled transaction rather than a reaction to immediate news.

Next Steps

• Vesting of 25% of 12,277 Restricted Stock Units annually over four years, starting from July 15, 2025.
• Earning and vesting of 30,692 performance shares on July 15, 2028, based on Incyte's relative Total Shareholder Return (TSR) over the three-year period beginning January 1, 2025.
• Employee stock options becoming exercisable in 37 installments, with the first 25% vesting after one year from July 15, 2025, and the remainder vesting monthly over three years.

Key Dates

Recommendation

Keywords

Incyte Corp, INCY, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Performance Shares, Employee Stock Options, Executive Compensation, Steven H. Stein, Biotechnology, Pharmaceuticals